CCR1 and neoplasm: Put together, these data suggest that Ly6G+ cells in the bone marrow of TH-302 and αVEGFR-2 treated mice actively proliferate and exit the bone marrow via CCR1 toward the tumor in response to combination TH-302 and VEGFR-2 blockade treatment.